Global Excipients Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2021

Colorcon to build new film coating manufacturing plant in Brazil
Colorcon Inc., a world leader in the development, supply and technical support of specialty excipients formulated film coating systems, modified release technologies, and functional excipients for the pharma industry, announced its investment in a new film coating manufacturing plant in Indaiatuba – São Paulo State, Brazil, supporting the continued growth of the pharmaceutical industry in South America. The construction is scheduled for completion by October 2016 with the production of commercial scale product scheduled for January 2017. Strategically located, the site will produce GMP film coating products for the pharmaceutical and nutritional markets in South America, including Argentina, Brazil, Chile, Paraguay and Uruguay.
http://www.pharmabiz.com/NewsDetails.aspx?aid=95022&sid=2
 
Eli Lilly launches Taltz in US market for moderate-to-severe plaque psoriasis treatment
Eli Lilly and Company announced that Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is made available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programmes to help ensure eligible patients have access to Taltz and available resources.  Taltz was approved by the US FDA in March 2016 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy or phototherapy. Taltz should not be used in patients with previous hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. Taltz is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.
http://www.pharmabiz.com/NewsDetails.aspx?aid=94956&sid=2
 
Dow India has multiple assets with an unmatched product mix of excipients worldwide
Dow Pharma and Food Solutions has launched an excipient, Methocel DC2, which reduces manufacturing costs and development time by 60 per cent. Savindu Kudrigikar, GM- Pharma Marketing, India, Dow Pharma & Food Solutions, states the outlook, defining trends, growth opportunities and new launches.
http://www.financialexpress.com/article/pharma/pharma-ally/%EF%BB%BFdow-india-has-multiple-assets-with-an-unmatched-product-mix-of-excipients-worldwide/34080/
 
BASF Extends Kollicoat Excipient Line
Kollicoat MAE 100-55 from BASF can be used as a direct substitute in commercial enteric pharmaceutical formulations. Kollicoat MAE 100-55, introduced by BASF, is a functional excipient for instant and modified release drugs that can replace comparable pH >5.5 enteric release materials in commercial formulations. The coating polymer matches the release profile and complies with applicable regulatory monographs and can be used without re-registration. The size of the dried powder particles delivers dust-free handling, and the product provides equivalent drug release as existing comparable products in the market.
http://www.pharmtech.com/basf-extends-kollicoat-excipient-line
 
IDEAL CURES becomes the First Indian Excipients Company to receive EXCiPACT™ Certification
IDEAL CURES PVT. LTD. is well known in the pharmaceutical excipients industry for a long time. IDEAL CURES PVT. LTD. becomes the first Indian company to receive EXCiPACT™ certification for its two manufacturing sites one at Jammu for film coating materials (INSTACOAT™, INSTANUTE™, INSTASPRAY™ and INSTAMASK™), Specialty products (Ecocool Extended Cooling Boosters - ECOCOOL™) and Neutral Spheres- ESPHERES™.  
http://uk.reuters.com/article/ideal-cures-pvt-ltd-idUKnBw045386a+100+BSW20150504
 
Colorcon expands Indian excipients site to capture generics market
Colorcon opened an expanded facility in Goa, India to scale up production of table coatings and excipients for pharmaceutical manufacturers in South Asia. The company has expanded the site to meet the increasing demand from local and multinational companies driven by greater access to medicine in the region. The Goa site will supply mostly generics clients, due to growing global demand for un-branded medicines and India’s sizeable market share of generics manufacturing.
http://nrsadvisors.com/colorcon-expands-indian-excipients-site-to-capture-generics-market/
 
Excipient industry group IPEC India launches after delays
Drug excipient makers in India and those serving the market have a dedicated IPEC chapter after the delayed fifth branch of the industry group was finally formally incorporated at the end of January.
http://www.pharma-excipients.ch/2014/03/10/excipient-industry-group-ipec-india-launches-after-delays/
 
Dow-Colorcon alliance launches excipient for pharma industry
Dow India and Colorcon have launched a new excipient, Methocel DC2 cellulose ethers, for the pharmaceutical industry in India. Designed to address productivity challenges, Methocel DC2 helps pharmaceutical companies to lower manufacturing costs by up to 60 percent and shorten development time, while improving tablet quality, claims Dow India.
http://www.business-standard.com/content/b2b-pharma/dow-colorcon-alliance-launches-excipient-for-pharma-industry-114121700034_1.html
 
Colorcon, Inc. Acquires Paulaur Corporation’s Pharmaceutical Sugar Spheres Business
Colorcon, Inc. announced the acquisition of the Pharmaceutical Sugar Spheres product line from Paulaur Corporation, a manufacturer of specialty sugar-based ingredients located in Cranbury, New Jersey. The addition of the Paulaur products complements Colorcon’s Suglets® Sugar Spheres product line and enhances Colorcon’s position as a leading global supplier of sugar spheres for the development of multiparticulate dosages. The agreement is specific to Paulaur sugar spheres sold into the pharmaceutical and nutritional segments globally. Colorcon provides speciality excipients for pharmaceutical and nutraceutical applications worldwide, and has identified strong synergies between the multiparticulate and film coating businesses. Colorcon is well-positioned to serve pharmaceutical and nutraceutical spheres customers thanks to its range of immediate, delayed and extended release coatings and previous investment in the multiparticulate business.
http://www.reuters.com/article/pa-colorcon-idUSnBw185167a+100+BSW20160118
 
Avantor and Rubicon Research to collaborate on novel excipients
Avantor Performance Materials has signed an agreement with Rubicon Research of Mumbai, India to develop and market a novel gastro-retentive excipient that enables the delivery of molecules with a window of absorption. The US firm says this excipient will enable the industry to develop more options in a niche segment where the benefit of targeted delivery will result in significant therapeutic advantage.
http://www.manufacturingchemist.com/news/article_page/Avantor_and_Rubicon_Research_to_collaborate_on_novel_excipients/81536
 

• DecisionDatabases.com also provides specific research reports as per Clients Requirement.
• Based on the feasibility, data as per custom segmentation can also be provided.

• Market Data Sheet With All Tables And Graphs
• Mini Report
• Market Analysis
  • Drivers
  • Restraints
  • SWOT Analysis
  • Patent Analysis
• Application Analysis
• Product Analysis
• Geography Analysis
• Company Analysis
• Competitive Landscape
• Location Of Plants
• Company Profiles